Rhonda Farnum, serving as the Senior Vice President of Communications and Medical Affairs at Theravance Biopharma, Inc. (NASDAQ:TBPH), has disposed of a significant block of company stock. On June 15, 2026, Farnum sold a total of 13,314 ordinary shares, with the transactions valued at approximately $218,167. The shares were liquidated through multiple trades, with execution prices ranging from $16.21 to $16.61 per share. These sales were carried out in strict compliance with a pre-arranged 10b5-1 trading plan that Ms. Farnum originally established on September 3, 2025. Following the completion of these transactions, Ms. Farnum continues to directly hold 232,457 ordinary shares in the company.
The insider transaction takes place against a backdrop of strong recent financial performance and mixed analyst sentiment regarding the stock's valuation. According to InvestingPro analysis, Theravance Biopharma shares currently trade at $16.71, reflecting a substantial 57% return over the past year. Despite this recent appreciation, the stock appears slightly overvalued relative to its Fair Value estimate, placing it on lists of overvalued equities. Investors seeking deeper insights can access comprehensive analysis through TBPH’s Pro Research Report, available for this and 1,400+ other US equities.
In other recent news, Theravance Biopharma reported its fourth-quarter results, including a non-GAAP net income of $3.1 million and year-end cash holdings of $326 million. The company also revealed fourth-quarter Yupelri revenue of $20.9 million, surpassing BTIG’s estimate of $19.8 million, marking another record quarter for the franchise. Full-year 2025 Yupelri sales reached $266.6 million, representing a 12% increase year-over-year, while fourth-quarter sales of $70.6 million rose 6% year-over-year.
BTIG reiterated its Buy rating on Theravance Biopharma, maintaining a price target of $21.00 due to the revenue beat. In contrast, TD Cowen raised its price target for the company to $15.00 from $13.00, while keeping a Hold rating, focusing on cash flow aspects. These developments highlight the company’s financial performance and analyst perspectives.
Theravance Biopharma Inc Follow Analyze TBPH Included in our AI-picked strategies Review strategies 16.71 ▲+0.02(+0.12%) Closed 16.71 0.00(0.00%) After Hours 13:30 14:00 15:00 15:30 16:00 16:30 17:00 18:00 18:30 19:00 19:30 16.5 16.6 16.7 Analyze TBPH This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Should you invest $2,000 in TBPH right now? ProPicks AI evaluates TBPH alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if TBPH is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space? Flash Sale - Price Goes Up Soon